Palvella Therapeutics (PVLA) to Release Quarterly Earnings on Monday

Palvella Therapeutics (NASDAQ:PVLA) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 31st. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.

Palvella Therapeutics Trading Up 0.9 %

Shares of Palvella Therapeutics stock traded up $0.26 during trading hours on Monday, reaching $28.40. 23,005 shares of the company’s stock were exchanged, compared to its average volume of 61,238. The business’s 50 day moving average is $18.78. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27. The firm has a market cap of $318.68 million, a PE ratio of -2.35 and a beta of 0.54.

Wall Street Analyst Weigh In

PVLA has been the topic of a number of research analyst reports. TD Cowen initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Scotiabank initiated coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $42.75.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.